The Airvo Device and Oxygen Administration in Chronic Obstructive Pulmonary Disease

Not Applicable

Recruiting

• Conditions: Chronic Obstructive Pulmonary Disease; Respiratory - Chronic obstructive pulmonary disease

• Registration Number: ACTRN12612000410853
• Lead Sponsor: Richard Beasley

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Diagnosis of chronic obstructive pulmonary disease with baseline oxygen saturations of 85-92%. A raise in transcutaneous carbon dioxide of greater than or equal to 4mmHg on eligibility testing (50% oxygen administration via a mask until transcutaneous carbon dioxide increases by greater than or equal to 4mmHg or for 20 minutes).

Exclusion Criteria

An intercurrent chest infection
FEV1>50% predicted
FEV1:FVC >0.7
Baseline transcutaneous carbon dioxide of greater than 60mmHg
Diagnosis of a disease causing restriction to chest wall expansion (neuromuscular disease or chest wall dysfunction)
Obesity (body mass index greater than or equal to 40)
Inability to tolerate the Airvo device at 25 and 45 Litres per minute
Any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Transcutaneous carbon dioxide, adjusted for baseline, measured via a TOSCA.[30 minutes.]